Deep Health AI India539559Quarterly results

Board approves Q2 and H1 FY27 results: profit Rs. 26.56 lacs in quarter, half-year loss of Rs. 163.34 lacs

Board of Deep Health AI India Ltd approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, at its meeting on November 03, 2026.

By ScoutQuest · Tue 3 Nov 2026, 8:43 PM IST · 3 min read

45.00 (Rs. in Lacs)-86.6%

Q2 FY26335.00 (Rs. in Lacs)Q2 FY2745.00 (Rs. in Lacs)

Revenue from operations (standalone: 335.00 (Rs. in Lacs) (Q2 FY26) and 45.00 (Rs. in Lacs) (Q2 FY27).

Standalone revenue from operations (Q2): Rs. 45.00 lacs for the quarter, against Rs. 335.00 lacs a year earlier
Profit for the quarter: Rs. 26.56 lacs (earlier Rs. 252.72 lacs)
Half year result: loss of Rs. 163.34 lacs

What the board approved

The board of Deep Health AI India Ltd met on Tuesday, November 03, 2026, from 03:00 P.M. to 07:35 P.M. and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the draft Limited Review Report. The statutory auditor, Vimal C. Surana & Co., Chartered Accountants, concluded that nothing had come to its attention that would suggest the statements are not prepared in line with the applicable standards and disclosure requirements. All figures below are in Rs. lacs unless stated otherwise.

Standalone performance: quarter ended 30.09.2026 vs 30.09.2025

Revenue from operations: 45.00 against 335.00.
Total income: 64.02 against 350.71.
Profit before tax: 38.14 against 337.75.
Profit for the period: 26.56 against 252.72.
Basic and diluted EPS (face value Rs.1/- each): 0.02 against 0.53.

Standalone performance: half year ended 30.09.2026 vs 30.09.2025

Revenue from operations: 90.00 against 350.00.
Total income: 125.63 against 384.39.
Profit/(loss) before tax: -151.76 against 350.27.
Profit/(loss) for the period: -163.34 against 262.10.
Basic and diluted EPS: -0.11 against 0.55.

The other comprehensive income line

Other comprehensive income for the quarter was -313.23 against 50.67 a year earlier, so total comprehensive income was -286.67 against 303.39.
The notes state that other comprehensive income represents fair value changes on equity instruments designated at fair value through other comprehensive income.
For the half year, other comprehensive income was -375.79; total comprehensive income was 212.45 against 338.18.

Balance sheet and cash (standalone)

Total assets: 5,450.23 as at 30th September, 2026, against 5,225.05 as at 31st March, 2026.
Cash and cash equivalents: 400.95 against 833.85.
Investments (non-current): 3,584.28 against 3,299.16.
Borrowings (current financial liabilities): 38.59 against 37.28.
Paid-up equity share capital: 1,441.50, face value of Rs.1/- each.

Two reportable segments

The company reports a Pharmaceutical Business and a Jewellery Business. For the quarter, Pharmaceutical revenue was 45.00 and Jewellery revenue 0.00; for the half year, 90.00 and 0.00.
Segment results for the quarter: Pharmaceutical 19.84, Jewellery 0.00.

Consolidated numbers and the associate

Consolidated revenue from operations: 45.00 for the quarter and 90.00 for the half year.
Share of loss from the associate: -5.63 for the quarter and -30.55 for the half year.
Consolidated profit for the quarter: 20.93 against 252.72; half year: -193.89 against 259.14.
The consolidated statement includes Ferry Automotive Private Limited as an associate company, with the parent holding 33.33%.

Land purchase agreement update

A memorandum of understanding dated 6th March, 2026 with Elegant Floriculture & Agrotech (India) Limited covers the purchase of agricultural land of approximately 4.91 hectares at Gut No. 358, Village Mouje Kashal, Taluka Maval, Pune, Maharashtra, for a total consideration of Rs. 18.00 crore.
As at 30th September, 2026, an advance of Rs. 5.29 crore had been paid and was carried as a capital advance.
By an addendum dated 30th October, 2026, the total consideration was revised to Rs. 19.50 crore; the aggregate advance is not to exceed Rs. 6.00 crore; an aggregate payment of Rs. 5.625 crore up to the date of the addendum was acknowledged, leaving a balance of Rs. 13.875 crore; and the time for paying the balance and executing the sale deed was extended up to one year from the date of the original agreement.

Trading window

The trading window for directors, KMPs, designated employees and connected persons has been closed from October 01, 2026 and will remain closed up to 48 hours after the declaration of these results.

What a retail reader can take from this

A results update like this gives an updated picture of revenue, profit, assets and cash, and lets the same line be compared across the current and previous periods. The notes explain what sits behind large swings, such as the fair value movement in equity investments and the share of loss from the associate. The land purchase addendum changes the consideration and the payment timeline, and states the balance still payable.

Also from Deep Health AI India